早期子宫内膜癌患者保留生殖内分泌功能治疗的研究进展

Development in the Treatment of Early Stage Endometrial Carcinoma by Saving the Function of Reproductive Endocinology

子宫内膜癌(endometrial carcinoma,EC)为女性生殖道常见三大恶性肿瘤之一,近年来发病率有上升趋势。虽然子宫内膜癌大多发生于绝经后妇女,但也有约25%的患者为绝经前女性,且3%～14%发生在40岁以下。其中未生育的年轻患者很难接受失去生育机会及卵巢内分泌功能。因此,近年来子宫内膜癌保留生殖内分泌功能的治疗,即保留年轻EC患者的生育功能或卵巢内分泌功能成为较关注的问题。近年研究表明,以孕激素为主治疗希望保留生理功能的年轻、早期、高分化子宫内膜癌患者是相对安全有效的。综述子宫内膜癌保留生育及卵巢功能的治疗现状。

Endometrial carcinoma（EC） is one of three most common malignant female genital carcinomas.The incidence of EC has been increased recently.Although it occurs mainly in the postmenopausal women,there are still 25% patients are premenopausal and 3%-14% patients are below 40 years old.It is hard for the younger nulliparous patients to accept the fact that they may lose their ability to give birth and the endocrine function of the ovaries.Thus,to preserve the fertility and endocrine function of the ovaries for the younger EC patients will be the attention problem.Recent years,present study indicates that primary treatment with megestrol acetate may be an effective and relatively safe choice of treatment of women with well-differentiated endometrial adenocarcinoma who wish to preserve the function of reproductive endocrinology.This article reviewed current literature of fertility and ovary function preservation treatment for those young patients with EC.